SCHEMBL4475121

SCHEMBL4475121

CCc1ccc(C(=O)N(C)C)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.41
MTOR P42345 2/20 0.41
KMT2A Q03164 1/20 0.40
RARB P10826 2/20 0.39
RARA P10276 1/20 0.39
RARG P13631 1/20 0.39
MAP2K2 P36507 1/20 0.39
MAP2K1 Q02750 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TRPA1 O75762 1/20 0.37
MAOB P27338 1/20 0.37
RIPK1 Q13546 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9970968 0.86 AR (0.45) PIK3CAMTORTRPA1RIPK1ALDH1A1
SCHEMBL4469757 0.85 HSP90AA1 (0.45) RARBRARARARGMAP2K2MAP2K1
SCHEMBL669282 0.82 RARB (0.54) KMT2ARARBRARARARGMAP2K2
SCHEMBL4518802 0.81 ALDH1A1 (0.41) KMT2ARARBHSP90AA1HSP90AB1PDK1
SCHEMBL14117285 0.81 TRPA1 (0.52) KMT2AHSP90AA1HSP90AB1PDK1PDK2
SCHEMBL14011194 0.80 MAOB (0.54) KMT2ARARBRARARARGMAP2K2
SCHEMBL4475971 0.79 ALDH1A1 (0.47) KMT2AHSP90AA1PDK1PDK2PDK4
SCHEMBL4508222 0.79 TRPA1 (0.37) KMT2AHSP90AA1HSP90AB1PDK1PDK2
SCHEMBL667823 0.79 ALDH1A1 (0.47) RARBRARARARGMAP2K2MAP2K1
SCHEMBL10211142 0.79 DGAT1 (0.55) RARBRARARARGMAP2K2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-16 US disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK PIK3CA 39/4885MTOR 235/4885KMT2A 1713/4885
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS LIPG, LPL, CEL PIK3CA 1055/4885MTOR 2302/4885KMT2A 1810/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK PIK3CA 39/4885MTOR 235/4885KMT2A 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.